Randomized Assessment of Rapid Endovascular Treatment of Ischemic Stroke (ESCAPE)
Source: View publication →
The ESCAPE trial demonstrated that among patients with acute ischemic stroke due to large vessel occlusion, a small infarct core, and good collateral circulation, rapid endovascular thrombectomy plus standard care significantly improved functional independence and reduced mortality compared to standard medical care alone.
Key Findings
Study Design
Study Limitations
Clinical Significance
The ESCAPE trial provided critical evidence supporting endovascular thrombectomy as the standard of care for acute ischemic stroke due to large vessel occlusion. It established that rapid reperfusion in carefully selected patients with preserved tissue significantly improves clinical outcomes and saves lives, shifting the paradigm of acute stroke management.
Historical Context
Published in early 2015, the ESCAPE trial was one of the pivotal 'second-wave' randomized controlled trials—along with MR CLEAN, SWIFT PRIME, REVASCAT, and EXTEND-IA—that definitively proved the efficacy of mechanical thrombectomy for large vessel occlusions, overturning previous neutral findings from earlier, less technologically advanced studies.
Guided Discussion
High-yield insights from every perspective
What is the physiological role of collateral circulation in the setting of an acute large vessel occlusion (LVO), and why did the ESCAPE trial prioritize patients with 'good' collaterals for thrombectomy?
Key Response
Collateral vessels provide retrograde blood flow to the ischemic penumbra, delaying the conversion of salvageable tissue into a non-viable infarct core. By selecting patients with good collaterals, the ESCAPE trial identified a 'slow-progressor' phenotype where the brain remains viable long enough for the benefits of mechanical reperfusion to significantly outweigh the risks of the procedure.
The ESCAPE trial used an ASPECTS (Alberta Stroke Program Early CT Score) threshold of 6 to 10 for inclusion. If a patient presents with an ASPECTS of 4 but has a confirmed M1 occlusion, how does the evidence from ESCAPE guide your decision-making compared to more recent 'large core' trials like SELECT2?
Key Response
ESCAPE established the standard of care for 'small to moderate core' strokes (ASPECTS 6-10), showing a massive benefit (NNT of ~3). While ESCAPE does not support treating an ASPECTS of 4, more recent data (SELECT2, TENSION) suggests benefit even in larger cores; however, the resident must recognize that ESCAPE’s specific workflow and inclusion criteria were optimized for high-probability success in preserved tissue.
ESCAPE utilized a unique multiphase CTA collateral imaging protocol rather than CTP (CT Perfusion). What are the practical and technical advantages of using multiphase CTA for patient selection in an acute stroke workflow compared to automated perfusion software?
Key Response
Multiphase CTA provides a temporal assessment of collateral filling without the technical pitfalls of CTP (e.g., motion artifacts, low cardiac output effects, or delayed bolus arrival). It is often faster to acquire and interpret, which directly supports the ESCAPE trial's emphasis on minimizing 'door-to-puncture' time, which is a critical determinant of functional outcome in endovascular therapy.
The ESCAPE trial achieved a median door-to-reperfusion time of 115 minutes, significantly faster than many contemporary trials. How should these results influence our institutional 'Direct-to-Angio' protocols and the trade-off between comprehensive diagnostic imaging and the speed of recanalization?
Key Response
ESCAPE demonstrated that the magnitude of benefit is time-sensitive even in patients with good collaterals. For the attending, the teaching point is that 'fast' is a relative term; the trial suggests that streamlining the pre-procedure phase (minimizing advanced imaging if CTA is sufficient) is the most impactful way to replicate these high functional independence rates in clinical practice.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The ESCAPE trial employed a group-sequential design that allowed for early termination for efficacy. From a statistical perspective, what are the primary concerns regarding effect size overestimation when a trial is stopped early, and how does the O’Brien-Fleming stopping boundary address these concerns?
Key Response
Trials stopped early for efficacy often report 'inflated' treatment effects (the 'random high' phenomenon). Using an O’Brien-Fleming boundary requires a very high level of statistical significance (low p-value) at early looks, which protects the Type I error rate and ensures that the evidence of benefit is robust enough that further recruitment would be unethical.
As a reviewer, how would you evaluate the threat to external validity posed by the fact that the ESCAPE trial was conducted in high-volume, highly specialized centers with exceptionally efficient workflows?
Key Response
A critical reviewer would flag that the 'ESCAPE effect' might not be reproducible in community settings where 'door-to-puncture' times are longer. The editor would require the authors to discuss whether the treatment's superiority is inherent to the device/procedure or if it is contingent upon the 'system of care' that allowed for such rapid reperfusion.
Based on the ESCAPE findings, should clinical guidelines mandate the use of collateral imaging (CTA or CTP) for all patients in the 0-6 hour window, or should LVO and ASPECTS remain the primary selection criteria?
Key Response
The 2019 AHA/ASA guidelines provide a Class I recommendation for EVT in patients meeting ESCAPE-like criteria (LVO, ASPECTS >=6). However, the committee must balance the 'ideal' selection (using collaterals) against the risk of delaying treatment in centers where advanced vascular imaging interpretation may not be immediately available. ESCAPE reinforces that while collateral status is a powerful modifier, the 'time-is-brain' imperative often favors the simplest imaging that confirms an LVO and a reasonable core.
Clinical Landscape
Noteworthy Related Trials
MR CLEAN Trial
Tested
Intraarterial treatment (thrombectomy)
Population
Patients with acute ischemic stroke due to proximal arterial occlusion in the anterior circulation
Comparator
Standard care (intravenous alteplase only)
Endpoint
Score on the modified Rankin scale at 90 days
SWIFT PRIME Trial
Tested
Solitaire stent retriever thrombectomy plus intravenous t-PA
Population
Patients with acute ischemic stroke due to large vessel occlusion
Comparator
Intravenous t-PA alone
Endpoint
Functional independence (modified Rankin scale 0-2) at 90 days
EXTEND-IA Trial
Tested
Endovascular thrombectomy with the Solitaire FR device
Population
Patients with ischemic stroke and large-vessel occlusion
Comparator
Intravenous alteplase
Endpoint
Reperfusion at 3 hours and functional outcome at 90 days
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis